Ipragliflozin [761423-87-4]

AdipoGen Life Sciences

Ipragliflozin [761423-87-4]

10

761423-87-4

Research Use Only

>98%

Warning

C21H21FO5S

404.5

Chemical. CAS: 761423-87-4. Formula: C21H21FO5S. MW: 404.5. Ipragliflozin is an orally active, highly potent sodium glucose co-transporter 2 (SGLT-2) inhibitor (IC50 = 7.4nM), selective over SGLT-1, 3, 4, 5 and 6. SGLT-2 is one subtype of SGLTs found almost exclusively in the proximal tubules of nephronic components in kidneys, playing a key role in the re-uptake of glucose in the proximal tubule of the kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Anti-diabetic and anti-obesity agent. Shown to improve glycemic control and reduce body weight, furthermore, lowering hypoglycemic risk and abdominal symptoms. SGLT-2 inhibitors are likely to improve beta-cell function and insulin sensitivity and restore glucose homeostasis. Attenuates non-alcoholic steatohepatitis (NASH) development. - Ipragliflozin is an orally active, highly potent sodium glucose co-transporter 2 (SGLT-2) inhibitor (IC50 = 7.4nM), selective over SGLT-1, 3, 4, 5 and 6. SGLT-2 is one subtype of SGLTs found almost exclusively in the proximal tubules of nephronic components in kidneys, playing a key role in the re-uptake of glucose in the proximal tubule of the kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Anti-diabetic and anti-obesity agent. Shown to improve glycemic control and reduce body weight, furthermore, lowering hypoglycemic risk and abdominal symptoms. SGLT-2 inhibitors are likely to improve beta-cell function and insulin sensitivity and restore glucose homeostasis. Attenuates non-alcoholic steatohepatitis (NASH) development.

FC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)=C2)=C2CC3=CC4=CC=CC=C4S3

-20°C,2°C to 8°C

12352200